

Special Issue

State-of-the-Art Hepatitis Research in 2022

Message from the Guest Editor

In recent decades, numerous studies focused on the virology, epidemiology, immunology, genetics, molecular biology, natural history, pathogenesis, current drug treatment, and new drug development in hepatitis research have strengthened our knowledge in this field. Such research provides the chance to identify and develop vaccines and treatments or cure viral hepatitis infections. Therefore, we welcome contributions to this Special Issue of *Viruses*, “State-of-the-Art Hepatitis Research in 2022”. The aim is to provide comprehensive information on all aspects of hepatitis research. Contributions to this Special Issue will advance our knowledge of hepatitis induced by virus infections and provide a better understanding of this serious human pathogen. This Special Issue will bring together original research papers and review manuscripts on hepatitis research with a focus on acute/chronic viral replication, pathogenesis, immune responses, vaccine development, hepatic disease, and antiviral treatments in viral hepatitis research.

Guest Editor

Dr. Youkyung Choi

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, The Centers for Disease Control and Prevention, Atlanta, GA 30329, USA

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/110888

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).